Skip to main content
Erschienen in: Current Sexual Health Reports 4/2019

28.10.2019 | Female Sexual Dysfunction and Disorders (T Lorenz and R Nappi, Section Editors)

Are There Any Sex/Gender Differences in Post-Selective Serotonin Reuptake Inhibitors (SSRI) Sexual Dysfunction (PSDD)?

verfasst von: Y. Reisman

Erschienen in: Current Sexual Health Reports | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Because of the sex/gender differences in the manifestation of depression, one can assume the possible existence of gender differences in post-SSRI sexual dysfunction (PSSD). This article tries to summarize the available data on sex/gender differences in PSSD and to evaluate if different approaches in diagnosis or treatment of different genders are needed.

Recent Findings

Depression is a leading cause of disability worldwide. Studies observed gender differences in prevalence and clinical presentation of depression, adherence to treatment and pharmacological features of antidepressant treatment. Sexual adverse events during the use of antidepressants are well-known and occur frequently. PSSD has been recently recognized as a medical condition that can outlast discontinuation of SSRI and SNRI antidepressants. The published literature on PSDD is lacking a clear definition of PSSD and data on possible sex/gender differences are very limited. The available information shows some gender differences in frequency of the different presented symptoms, but development of validated clinical assessment instruments of all possible sexual complaints, including genital anesthesia and pleasureless orgasm, is necessary.

Summary

The available scientific literature is lacking profound information about the extent, the mechanism, and possible treatment of PSSD and sex/gender differences as well. Physicians should assess sexual function prior, during, and also after treatment with antidepressants and be aware of the possibility of PSSD. Physicians should inform their patients about the possible sexual consequences of antidepressant treatment and include it, when possible, in the treatment decision-making process.
Literatur
1.
Zurück zum Zitat APA. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington: American Psychiatric Association, 2013 APA. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington: American Psychiatric Association, 2013
3.
Zurück zum Zitat Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet. 1997;349(9061):1269–76.CrossRef Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet. 1997;349(9061):1269–76.CrossRef
4.
Zurück zum Zitat Üstün TB, Ayuso - Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184:386–92.CrossRef Üstün TB, Ayuso - Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184:386–92.CrossRef
5.
Zurück zum Zitat Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8–19.CrossRef Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8–19.CrossRef
6.
Zurück zum Zitat Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:21–7. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:21–7.
8.
Zurück zum Zitat Angold A, Costello EJ, Erkanli A, Worthman CM. Pubertal changes in hormone levels and depression in girls. Psychol Med. 1999;29(5):1043–53.CrossRef Angold A, Costello EJ, Erkanli A, Worthman CM. Pubertal changes in hormone levels and depression in girls. Psychol Med. 1999;29(5):1043–53.CrossRef
9.
Zurück zum Zitat Brown GW, Harris TO, Eales MJ. Social factors and comorbidity of depressive and anxiety disorders. Br J Psychiatry Suppl. 1996;30:50–7.CrossRef Brown GW, Harris TO, Eales MJ. Social factors and comorbidity of depressive and anxiety disorders. Br J Psychiatry Suppl. 1996;30:50–7.CrossRef
10.
Zurück zum Zitat Bigos KL, Pollock BG, Stankevich BA, Bies RR. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gend Med. 2009;6(4):522–43.CrossRef Bigos KL, Pollock BG, Stankevich BA, Bies RR. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gend Med. 2009;6(4):522–43.CrossRef
12.
Zurück zum Zitat Kornstein SG, Sloan DME, Thase ME. Gender-specific differences in depression and treatment response. Psychopharma Bulletin. 2002;36(supp3):99–112. Kornstein SG, Sloan DME, Thase ME. Gender-specific differences in depression and treatment response. Psychopharma Bulletin. 2002;36(supp3):99–112.
13.
Zurück zum Zitat Baca E, Garcia-Garcia M, Porras-Chavarino A. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Prog Neuro-Psychopharmacol Biol Psychiatry. 2004;28(1):57–65.CrossRef Baca E, Garcia-Garcia M, Porras-Chavarino A. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Prog Neuro-Psychopharmacol Biol Psychiatry. 2004;28(1):57–65.CrossRef
14.
Zurück zum Zitat Staley JK, Krishnan-Sarin S, Zoghbi S, et al. Sex differences in 123Iβ-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse. 2001;41(4):275–84.CrossRef Staley JK, Krishnan-Sarin S, Zoghbi S, et al. Sex differences in 123Iβ-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse. 2001;41(4):275–84.CrossRef
15.
Zurück zum Zitat Cidis Meltzer C, Drevets WC, Price JC, Mathis CA, Lopresti B, Greer PJ, et al. Gender-specific aging effects on the serotonin 1A receptor. Brain Res. 2001;895(1-2):9–17. Cidis Meltzer C, Drevets WC, Price JC, Mathis CA, Lopresti B, Greer PJ, et al. Gender-specific aging effects on the serotonin 1A receptor. Brain Res. 2001;895(1-2):9–17.
16.
Zurück zum Zitat Laakso A, Vilkman H, Bergman J, Haaparanta M, Solin O, Syvälahti E, et al. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol Psychiatry. 2002;52(7):759–63.CrossRef Laakso A, Vilkman H, Bergman J, Haaparanta M, Solin O, Syvälahti E, et al. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol Psychiatry. 2002;52(7):759–63.CrossRef
19.
Zurück zum Zitat Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry. 2001;62(suppl 3):10–21.PubMed Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry. 2001;62(suppl 3):10–21.PubMed
21.
Zurück zum Zitat Bolton JM, Sareen J, Reiss JP. Genital anesthesia persisting six years after sertraline discontinuation. J Sex Marital Ther. 2006;32(4):327–30.CrossRef Bolton JM, Sareen J, Reiss JP. Genital anesthesia persisting six years after sertraline discontinuation. J Sex Marital Ther. 2006;32(4):327–30.CrossRef
22.
Zurück zum Zitat Csoka AB, Shipko S. Persistent sexual side effects after SSRI discontinuation. Psychother Psychosom. 2006;75(3):187–8.CrossRef Csoka AB, Shipko S. Persistent sexual side effects after SSRI discontinuation. Psychother Psychosom. 2006;75(3):187–8.CrossRef
23.
Zurück zum Zitat Bahrick AS. Post SSRI sexual dysfunction. American Society for the Advancement of Pharmacotherapy Tablet. 2006;7(3):2–3 10-11. Bahrick AS. Post SSRI sexual dysfunction. American Society for the Advancement of Pharmacotherapy Tablet. 2006;7(3):2–3 10-11.
24.
Zurück zum Zitat Kauffman RP, Murdock A. Prolonged post-treatment genital anesthesia and sexual dysfunction following discontinuation of citalopram and the atypical antidepressant nefazodone. The Open Women’ Health Journal. 2007;1:1–3.CrossRef Kauffman RP, Murdock A. Prolonged post-treatment genital anesthesia and sexual dysfunction following discontinuation of citalopram and the atypical antidepressant nefazodone. The Open Women’ Health Journal. 2007;1:1–3.CrossRef
25.
Zurück zum Zitat Ekhart GC, Van Puijenbroek EP. Blijvende seksuele functiestoornissen na staken van een SSRI? Tijdschrijft Psychiatrie. 2014;56:336–40. Ekhart GC, Van Puijenbroek EP. Blijvende seksuele functiestoornissen na staken van een SSRI? Tijdschrijft Psychiatrie. 2014;56:336–40.
29.
Zurück zum Zitat • Citizen petition: sexual side effects of SSRIs and SNRIs. Internat J Risk & Safety in Medicine 2018;29:135–147. https://doi.org/10.3233/JRS-180745summarize to healthcare providers and policy makers the information available about sexual side-effects and possible long-term consequences of antidepressants use • Citizen petition: sexual side effects of SSRIs and SNRIs. Internat J Risk & Safety in Medicine 2018;29:135–147. https://​doi.​org/​10.​3233/​JRS-180745summarize to healthcare providers and policy makers the information available about sexual side-effects and possible long-term consequences of antidepressants use
32.
Zurück zum Zitat Stinson RD. The impact of persistent sexual side effects of selective serotonin reuptake inhibitors after discontinuing treatment: a qualitative study. PhD (Doctor of Philosophy) thesis, University of Iowa, 2013. http://ir.uiowa.edu/etd/5061. Stinson RD. The impact of persistent sexual side effects of selective serotonin reuptake inhibitors after discontinuing treatment: a qualitative study. PhD (Doctor of Philosophy) thesis, University of Iowa, 2013. http://​ir.​uiowa.​edu/​etd/​5061.
34.
Zurück zum Zitat Adson DE, Kotlyar M. Premature ejaculation associated with citalopram withdrawal. Ann Pharmacother. 2003;37(12):1804–6.CrossRef Adson DE, Kotlyar M. Premature ejaculation associated with citalopram withdrawal. Ann Pharmacother. 2003;37(12):1804–6.CrossRef
Metadaten
Titel
Are There Any Sex/Gender Differences in Post-Selective Serotonin Reuptake Inhibitors (SSRI) Sexual Dysfunction (PSDD)?
verfasst von
Y. Reisman
Publikationsdatum
28.10.2019
Verlag
Springer US
Erschienen in
Current Sexual Health Reports / Ausgabe 4/2019
Print ISSN: 1548-3584
Elektronische ISSN: 1548-3592
DOI
https://doi.org/10.1007/s11930-019-00222-x

Weitere Artikel der Ausgabe 4/2019

Current Sexual Health Reports 4/2019 Zur Ausgabe

Urology, Gynecology, and Endocrinology (J Simon and M Luria, Section Editors)

Premature Ejaculation: 2020 Update

Male and Female Surgical Interventions (C Carson and M Khera, Section Editors)

Surgical Techniques and Pitfalls for Excision and Grafting

Male Sexual Dysfunction and Disorders (A Pastuszak and N Thirumavalavan, Section Editors)

Climacturia (Uroclimax) in Men After Radical Prostatectomy: A Comprehensive Review of the Current Literature and Treatment Strategies

Female Sexual Dysfunction and Disorders (A Pastuszak and N Thirumavalavan, Section Editors)

Management of the Acute Phase of Peyronie’s Disease: a Contemporary Review

Female Sexual Dysfunction and Disorders (T Lorenz & R Nappi, Section Editors)

Female Sexual Dysfunction as a Warning Sign of Chronic Disease Development

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.